Amoxicillin
FDA-approved product (capsule, oral), marketed as Amoxicillin, Amoxicillin Pediatric, Amoxil and 7 more.
- Registered studies
- 50+
- Lab records
- 107
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Duodenal ulcer
- Gonorrhea
- Infection
- Infectious otitis media
- Otitis media
- Pharyngitis
- Pneumonia
- Recurrent tonsillitis
- Respiratory tract infectious disorder
- Sinusitis
- Soft Tissue Infections
- Tonsillitis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Penicillins with extended spectrum
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CA04
Repurposing investigation
Amoxicillin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA85.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae5.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 20 of 26 lab records
- E. coli: measured active in 5 of 10 lab records
- K. pneumoniae: measured active in 3 of 71 lab records
Show the 107 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Amoxicillin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Enhancing Amoxicillin Pharmacokinetics and Pharmacodynamics Parameters With Probenecid in Bone and Joint Infections
NCT07764302 · start 2026-12
Registered record
- Registry ID
- NCT07764302
- Conditions
- Osteoarticular Infections (OAIs)
- Interventions
- Oral probenecid added to oral amoxicillin for osteoarticular infections
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Not yet recruiting
- Start
- 2026-12
- Completion
- 2029-09
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarticular Infections (OAIs)InterventionOral probenecid added to oral amoxicillin for osteoarticular infectionsPhasePhase 3Registry statusNot yet recruitingExtended Azithromycin Treatment in Prelabor Rupture of Membranes
NCT07669207 · start 2026-08-19
Registered record
- Registry ID
- NCT07669207
- Conditions
- Preterm Prelabor Rupture of Membranes; PPROM
- Interventions
- Azithromycin (Azithro); Standard Azithromycin Dosing
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2026-08-19
- Completion
- 2028-07
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPreterm Prelabor Rupture of Membranes; PPROMInterventionAzithromycin (Azithro); Standard Azithromycin DosingPhasePhase 4Registry statusRecruitingEffect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
NCT07576959 · start 2026-04-08
Registered record
- Registry ID
- NCT07576959
- Conditions
- HELICOBACTER PYLORI INFECTIONS
- Interventions
- Bismuth Add-on to Vonoprazan Dual Therapy; Vonoprazan dual therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2026-04-08
- Completion
- 2032-12-31
- Enrolment
- 990
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHELICOBACTER PYLORI INFECTIONSInterventionBismuth Add-on to Vonoprazan Dual Therapy; Vonoprazan dual therapyPhasePhase 3Registry statusRecruitingTraditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis
NCT07323888 · start 2026-03-01
Registered record
- Registry ID
- NCT07323888
- Conditions
- Nasal Obstruction; Chronic Rhinitis; Nonallergic Rhinitis; Rhinorrhea; Inferior Turbinate Hypertrophy
- Interventions
- Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation; Traditional Radiofrequency Ablation of Inferior Turbinates
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2026-03-01
- Completion
- 2027-05-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNasal Obstruction; Chronic Rhinitis; Nonallergic Rhinitis; Rhinorrhea +1 moreInterventionTraditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation; Traditional Radiofrequency Ablation of Inferior TurbinatesPhaseNot applicableRegistry statusActive not recruitingThe Effect of Different Antibiotic Protocols on Peri-implant Tissue Health
NCT06378502 · start 2024-05-03
Registered record
- Registry ID
- NCT06378502
- Conditions
- Antibiotic
- Interventions
- Amoxicillin Short; Amoxicillin Long
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2024-05-03
- Completion
- 2026-06-30
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAntibioticInterventionAmoxicillin Short; Amoxicillin LongPhasePhase 4Registry statusUnknownComparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection (SHARE2301)
NCT05870683 · start 2023-05-24
Registered record
- Registry ID
- NCT05870683
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Tegoprazan; Amoxicillin; Esomeprazole
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2023-05-24
- Completion
- 2023-12-30
- Enrolment
- 368
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionTegoprazan; Amoxicillin; EsomeprazolePhaseNot applicableRegistry statusUnknownHelicobacter Pylori and Vonoprazan Dual Therapy
NCT05649709 · start 2023-02-13
Registered record
- Registry ID
- NCT05649709
- Conditions
- Helicobacter Pylori
- Interventions
- L-VA dual therapy; H-VA dual therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-02-13
- Completion
- 2024-01-25
- Enrolment
- 504
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter PyloriInterventionL-VA dual therapy; H-VA dual therapyPhasePhase 4Registry statusCompletedThe Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation
NCT04552080 · start 2022-12-29
Registered record
- Registry ID
- NCT04552080
- Conditions
- Patients Undergoing Oral Implant Therapy
- Interventions
- Amoxicillin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2022-12-29
- Completion
- 2026-03
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPatients Undergoing Oral Implant TherapyInterventionAmoxicillin; PlaceboPhasePhase 4Registry statusUnknownAbsorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
NCT05302531 · start 2022-12-09
Registered record
- Registry ID
- NCT05302531
- Conditions
- Short Bowel Syndrome; Infection, Bacterial
- Interventions
- Amoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprim
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2022-12-09
- Completion
- 2025-02
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionShort Bowel Syndrome; Infection, BacterialInterventionAmoxicillin; Levofloxacin; Ofloxacin; Sulfamethoxazole trimethoprimPhasePhase 1Registry statusUnknownOne vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL
NCT05728424 · start 2022-09-20
Registered record
- Registry ID
- NCT05728424
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Vonoprazan, Amoxicillin, Levofloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2022-09-20
- Completion
- 2023-05-01
- Enrolment
- 246
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionVonoprazan, Amoxicillin, LevofloxacinPhasePhase 3Registry statusUnknownEfficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication
NCT05469685 · start 2022-08-01
Registered record
- Registry ID
- NCT05469685
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Vonoprazan; Amoxicillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-08-01
- Completion
- 2023-09-30
- Enrolment
- 914
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionVonoprazan; AmoxicillinPhasePhase 4Registry statusCompletedBismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.
NCT05432115 · start 2022-06-25
Registered record
- Registry ID
- NCT05432115
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Tetracyclin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2022-06-25
- Completion
- 2023-10
- Enrolment
- 407
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionTetracyclinPhasePhase 4Registry statusUnknownCollaborative Urological Prosthetics Investigation Directive Research Group
NCT05100654 · start 2022-04-22
Registered record
- Registry ID
- NCT05100654
- Conditions
- Erectile Dysfunction; Penile Prosthesis Infection
- Interventions
- Doxycycline; Ciprofloxacin; Augmentin; Bactrim
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Active not recruiting
- Start
- 2022-04-22
- Completion
- 2028-01-01
- Enrolment
- 800
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile Dysfunction; Penile Prosthesis InfectionInterventionDoxycycline; Ciprofloxacin; Augmentin; BactrimPhaseEarly phase 1Registry statusActive not recruitingBismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
NCT04901117 · start 2021-06
Registered record
- Registry ID
- NCT04901117
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-06
- Completion
- 2023-08
- Enrolment
- 1,300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 morePhasePhase 4Registry statusUnknownEffects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children
NCT05378022 · start 2020-12-21
Registered record
- Registry ID
- NCT05378022
- Conditions
- Acute Respiratory Tract Infections
- Interventions
- LiveSpo Navax; 0.9% NaCl physiological saline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2020-12-21
- Completion
- 2022-04-22
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Respiratory Tract InfectionsInterventionLiveSpo Navax; 0.9% NaCl physiological salinePhaseNot applicableRegistry statusCompleted